Opioid quantification via microsampling techniques to assess opioid use in human laboratory studies DOI Creative Commons

Ramisa Fariha,

Emma Rothkopf,

Carolina L. Haass‐Koffler

et al.

Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)

Published: May 21, 2025

Despite progress in neurobiological studies with human subjects, sample availability remains a challenge. Urine samples, widely used for screening, suffer from false-positive results due to immunoassay cross-reactivity. Serum, confirmatory testing, offers advantages but faces limitations blood collection. Microsamples, working volume less than 50 μL, present an ideal strategy robust quantitative data collection investigations and laboratory studies. We developed, validated, automated serum-based LC-MS/MS assay accurate quantification of six opioids using only 20 μL patient samples. Our method, applied clinical trial patients opioid use disorder (N = 20) receiving intranasal oxytocin, or placebo, one week addition agonist therapy (buprenorphine methadone). quantified different opioids, undetected by urine strip tests, that were during the treatment phase. high-throughput, approach surpasses existing methods literature, enhancing efficiency multi-matrix

Language: Английский

Opioid quantification via microsampling techniques to assess opioid use in human laboratory studies DOI Creative Commons

Ramisa Fariha,

Emma Rothkopf,

Carolina L. Haass‐Koffler

et al.

Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)

Published: May 21, 2025

Despite progress in neurobiological studies with human subjects, sample availability remains a challenge. Urine samples, widely used for screening, suffer from false-positive results due to immunoassay cross-reactivity. Serum, confirmatory testing, offers advantages but faces limitations blood collection. Microsamples, working volume less than 50 μL, present an ideal strategy robust quantitative data collection investigations and laboratory studies. We developed, validated, automated serum-based LC-MS/MS assay accurate quantification of six opioids using only 20 μL patient samples. Our method, applied clinical trial patients opioid use disorder (N = 20) receiving intranasal oxytocin, or placebo, one week addition agonist therapy (buprenorphine methadone). quantified different opioids, undetected by urine strip tests, that were during the treatment phase. high-throughput, approach surpasses existing methods literature, enhancing efficiency multi-matrix

Language: Английский

Citations

0